#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic scleroderma Ductal adenocarcinoma of pancreas Retinal artery occlusion Scleroderma associated digital ulcer Muscular dystrophy Thyroid cancer metastatic Malignant melanoma Chronic hepatitis B Sjogren's syndrome Glomerulonephritis membranoproliferative Interstitial lung disease Brain stem glioma Univentricular heart Germ cell cancer Primitive neuroectodermal tumour More trials…

    Learn about Rare Diseases

    Alternating hemiplegia of childhood – Treatment Mastocytosis – Basic Information Undifferentiated sarcoma – Life with Disease Congenital generalised lipodystrophy – Basic Information Prader-Willi syndrome – Diagnostics Hepatoblastoma – Treatment Loeys-Dietz syndrome Chondrosarcoma – Life with Disease IgA nephropathy – Diagnostics Cytokine release syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Opevesostat Tosilate Lithium Fenfluramine Hydrochloride D-Camphor Emedastine Vonafexor Potassium Iodide Tigulixostat Midazolam Hydrochloride Fluorodopa (18F) Dosulepin Hydrochloride GSKVX000000025896 Ambroxol Hydrochloride HUPERZINE A PIROXICAM Taxanes Efavirenz FG001 Ramipril Gtaexs617 More therapies…

    Learn about Your Condition

    Alveolar proteinosis Skin neoplasm excision Delirium Mental disorder Renal impairment Hyperoxaluria Anaemia of chronic disease Lennox-Gastaut syndrome Angiosarcoma metastatic Urea cycle disorder Multiple sclerosis relapse Osteoporosis Ventricular fibrillation CADASIL Glomerulonephritis chronic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Medical Center Akad. Iv. Penchev EOOD

Medical Center Akad. Iv. Penchev EOOD

Ulitsa Zdrave 2, Sofia, 1431, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • Study of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Metformin Embonate
    Bulgaria Croatia Germany Greece Hungary Poland +3

  • Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hypertriglyceridaemia
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Belgium Bulgaria Croatia Czechia France Germany +8

  • Study on How Cagrilintide and Semaglutide Help People with Overweight or Obesity Reduce Weight

    Not recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Belgium Bulgaria Denmark Finland France Germany +4

  • Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

    Not recruiting

    4 1 1
    Austria Bulgaria Germany Italy The Netherlands Poland +2

  • Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Chronic kidney disease
    • Type 2 diabetes mellitus
    • Obesity
    Investigated Drugs:
    • Semaglutide
    Bulgaria Italy Poland Spain

  • Study of Lu AG22515 for Adults with Moderate-to-Severe Thyroid Eye Disease

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Endocrine ophthalmopathy
    Investigated Drugs:
    • Human (Scfv)2-Fab Fusion Protein Against Cd40L
    Bulgaria Germany Poland Spain

  • Study on the Safety and Effectiveness of Paltusotine for Patients with Acromegaly

    Not recruiting

    3 1
    Investigated Drugs:
    • Paltusotine
    Belgium Bulgaria France Hungary Italy Poland

  • Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

    Not recruiting

    3 1
    Investigated Drugs:
    • Paltusotine
    Bulgaria France Germany Greece Hungary Italy +1

  • Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

    Not recruiting

    3 1
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Bulgaria Czechia France Germany Hungary Latvia +4

  • Study of SPI-62 for Treating ACTH-Dependent Cushing’s Syndrome in Patients with Cushing’s Disease or Ectopic ACTH/CRH Secretion

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Clofutriben
    Bulgaria Romania
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!